Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06580002 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2026 to Jul 2027 Enrollment target: 51 to 75 · Eligibility criteria expanded, about 69 wordsv5 Show 2 more changesShow less
    • Enrollment target: 51 to 75
    • Eligibility criteria expanded, about 69 words

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 34 to 51 Primary completion date: Dec 2025 to Dec 2026 · Primary endpoint revised · Completion date: Dec 2026 to Dec 2027 · 1 morev4 Show 4 more changesShow less
    • Primary completion date: Dec 2025 to Dec 2026
    • Primary endpoint revised
    • Completion date: Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Eligibility criteria expanded, about 1 wordv3 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Sep 2025 to Dec 2025 · Completion date: Sep 2026 to Dec 2026 · Start date changed from estimate of Sep 2024 to Dec 2, 2024 · 3 morev2 Show 6 more changesShow less
    • Primary completion date: Sep 2025 to Dec 2025
    • Completion date: Sep 2026 to Dec 2026
    • Start date changed from estimate of Sep 2024 to Dec 2, 2024
    • Eligibility criteria expanded, about 213 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of California, Irvine
152 trials monitored
See 13 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 14 more diseases
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.
Trial Details
NCT Number NCT06580002
Lead Sponsor University of California, Irvine
Conditions Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer +14 more
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov